Session 3

Use of Clinical Outcome Assessment Tools in Multinational Trials

Ashley Slagle, MS, PhD
Study Endpoints
Office of New Drugs
Center for Drug Evaluation and Research
Food & Drug Administration
April 1, 2015

Session 3 Participants

Speakers
• Maria Isaac, MASc, MD, PhD, MFPM, EMA
• Andrew Mulberg, MD, FAAP, FDA
• Donald Patrick, PhD, MSPH, University of Washington
• Debra Silberg, MD, PhD, Shire
• Laura Lee Johnson, PhD, FDA
Key Learnings From PDUFA V Patient-Focused Drug Development (PFDD)

Theresa Mullin, PhD  
Director, Office of Strategic Programs  
FDA CDER

PFDD Work to Date

- FDA is convening 20+ meetings to obtain patient perspectives in specific disease areas
- Questions FDA asks in these meetings include:
  - Which symptoms have the most significant impact on your daily life?... On your ability to do specific activities?
  - How well does your current treatment regimen treat the most significant symptoms of your disease?
  - What specific things would you look for in an ideal treatment for your condition?
  - What factors do you take into account when making decisions about using treatments? ... Deciding whether to participate in a clinical trial?

PFDD meetings FY 2013-2015

<table>
<thead>
<tr>
<th>Fiscal Year 2013</th>
<th>Fiscal Year 2014</th>
<th>Fiscal Year 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic fatigue syndrome/ myalgic encephalomyelitis</td>
<td>Sickle cell disease</td>
<td>Female sexual dysfunction to be conducted</td>
</tr>
<tr>
<td>HIV</td>
<td>Fibromyalgia</td>
<td>Breast cancer (April 2)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Pulmonary arterial hypertension</td>
<td>Chagas disease (April 28)</td>
</tr>
<tr>
<td>Narcolepsy</td>
<td>Inborn errors of metabolism</td>
<td>Functional gastrointestinal disorders (May 11)</td>
</tr>
<tr>
<td></td>
<td>Hemophilia A, B, and other heritable bleeding disorders</td>
<td>Alpha-1 antitrypsin deficiency</td>
</tr>
<tr>
<td></td>
<td>Idiopathic pulmonary fibrosis</td>
<td>Parkinson's disease and Huntington's disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>In-Person</th>
<th>Registered</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient / Representatives</td>
<td>40 – 185</td>
<td>30 – 80</td>
</tr>
<tr>
<td>Other (e.g., NIH, industry)</td>
<td>40 – 115</td>
<td>30 – 140</td>
</tr>
<tr>
<td>Webcast</td>
<td>250 – 650</td>
<td>~50% of registered</td>
</tr>
<tr>
<td>Docket Submissions</td>
<td>5 - 400</td>
<td></td>
</tr>
</tbody>
</table>

PFDD Learnings to Date

- Patients with chronic serious disease are experts on what it’s like to live with their condition
- They want their experience described using words that they consider to best describe how it feels
- Among the diseases in PFDD meetings to date, the most prominent impacts (symptoms, loss of function) are primarily physiological and often observed and confirmed by other family members
- For progressive degenerative diseases, many patients/parents feel an ideal treatment would at minimum stop progression of their/their child’s loss of function
PFDD Learnings to Date (cont)

- Patients’ “chief complaints” may not be factored explicitly into drug development plans, including measures of drug benefit planned in trials.
- Patients want to be as active as possible in the work to develop and evaluate new treatments.
- They and their caregivers are able and willing to engage via the Internet, social media, and all other means at their disposal.
- They are not expecting for FDA to address all the gaps in current treatment or current approaches to drug development but do want FDA to help identify most effective pathways for them to play major contributing role.

FDA Potential Next Steps

- Advance science of patient input engaging wider community to discuss:
  - Methodologically sound approaches to bridge from initial patient-focused meetings to more systematic collection of patients’ experience living with a particular disease.
  - How to best proceed in obtaining patients’ reports, assessments, and preferences, to inform patient-centered development and benefit risk assessment.
    - Approaches to recording patients’ experiences of impact (burden) of disease over time.
    - Understanding preferences for treatment impacts and tolerance of uncertainty about meaningful, significant potential benefits versus harms.
- Provide guidance to patient advocates and drug developers.

Where Do We Go From Here?

Questions for our Session 4 Panelists--

From their perspective:

- What are key elements of strategy going forward?
- What actionable next steps do you think need to be taken in the next 2-5 years?
Choice of COA Type

• Determine the most appropriate reporter for the COI in the COU

  If symptom intensity is the concept of interest in a patient population that can respond themselves, a PRO is most appropriate.

  If clinical judgment is required to interpret an observation, a ClinRO is chosen.

  If the COI can only be adequately captured by observation in daily life (outside of a healthcare setting), and the patient cannot report for him or herself, then an ObsRO is chosen.

  When it would be useful to observe an actual demonstration of defined tasks demonstrating functional performance in the clinical setting, a PerfO may be appropriate.

Practical Advice on the Development and Use of Clinical Outcome Assessment Tools in Multinational Trials

Laura Lee Johnson, Ph.D.
Office of Biostatistics
Center for Drug Evaluation and Research
Food and Drug Administration

Disclaimer

• This presentation reflects the views of the author and should not be construed to represent FDA’s views or policies.

Risk and Benefit to Early Translation

• Backing in to cognitive, pediatric, and multi-regional issues can be costly

• Broad development work is also costly

• Practical advice
  – Drug development timeline
  – Pooling data
  – Data collection issues

• “Review Issue”
Not Only COAs

<table>
<thead>
<tr>
<th>Stroke or SEE by Region</th>
<th>mITT On-Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Region</td>
<td>%</td>
</tr>
<tr>
<td>North America</td>
<td>9.70</td>
</tr>
<tr>
<td>Latin America</td>
<td>9.50</td>
</tr>
<tr>
<td>Europe</td>
<td>9.30</td>
</tr>
<tr>
<td>Japan</td>
<td>9.54</td>
</tr>
</tbody>
</table>

Daichi-Sankyo presentations for the October 30, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee, Slide 87 (Subgroup Analyses) by Glen Gormley, MD, PhD

Early!

- When to think about
  - Translatability
  - Translation
  - Adaptation
- Literacy
- Pediatrics
- Multi regional studies

Roadmap to **PATIENT-FOCUSED OUTCOME MEASUREMENT** in Clinical Trials

- They do not differ that much
- Using and citing them will go a long way
- There are costs to NOT attending to these issues early

Many Good Practice Guidelines Available
Further Information

- ICH E5: Ethnic Factors in the Acceptability of Foreign Clinical Data (www.ich.org)
  - The Q&A section is especially helpful
- Multi-regional Clinical Trials – Considerations in Design and Analysis, Aloka G. Chakravarty, Ph.D.

Thank You
Cultural Adaptation of Clinical Outcome Assessments in Multinational Trials

Donald L. Patrick, PhD, MSPH
University of Washington

Presentation at PDUFA V Clinical Outcomes Assessment Public Workshop
White Oak Campus, Food and Drug Administration, 1 April 2015

The Context

Growing Interest in COAs

Development of COA instruments... in only one language (UK/US/CAN English)

Adaptation for use in global clinical trials

Translation & Cultural adaptation

Differences in COAs require new considerations in cultural adaptation

EXAMPLES:
What is the appropriate adaptation process when doctors ask patients questions in their interview and their answers generate trial data?

- How should patients, clinicians and observers be involved in the translation process for the specific COAs?
- How does the process accommodate growing migrant populations and sub populations?
- What new considerations are needed for use with the wide variety of electronic platforms and devices?

Why is a specialized methodology necessary?

Globalization of Clinical Research: Over 60% of pivotal studies submitted to CDER in 1967 contained data from one or more foreign study sites (6 out of 10 of the studies)*

Need for cross-cultural equivalence to allow for pooling and comparison of data across countries

Cultural adaptation first step towards achieving and testing cross-cultural equivalence.

*Ayalew K. FDA Perspective on International Clinical Trials. December 12, 2013
Why is it important to do more than basic translation?

Why do we need cultural adaptation?

Translation - Cultural Adaptation

- **Translation**
  - Act of bilingual communication
  - (a rendering from one language into another; also: the product of such a rendering - Merriam-Webster)
  - Made possible because of parallelisms in thoughts and situations = transcoding operation
  - (representation of reality is coded differently in different languages)

- **Cultural Adaptation**
  - Process used to make COAs useful in multiple languages/cultures
  - Implies several steps, using translation techniques, but also test on target populations (patients or healthy subjects)
  - More than a simple translation

---

Orange Campaign in UK

"The future's bright – the future's Orange"

Orange was a mobile network operator and internet service provider in the United Kingdom, launched in 1993. 2009: Orange UK has since merged with Deutsche Telekom's T Mobile UK to form a joint venture, EE.

Not for the Catholics of Northern Ireland!!

They do not see the future as Protestant!!

Example in conceptual analysis

Questionnaire: Health Assessment Questionnaire (HAQ)

- Original: US English
- Eating category: Are you able to cut your meat?
- What is the concept behind this item?
- Concept: to assess patient's ability to do micro movements of the upper extremity (functional ability)
**Item in Cultural Adaptation**

Questionnaire: Health Assessment Questionnaire (HAQ)
- Original: US English
- Eating category: Are you able to cut your meat?
- Target language: Hindi/India
- Concept: To assess patient's ability to do micro movements of the upper extremity (functional ability).
- Linguistic/cultural problems?
  - Use of cutlery, vegetarianism
- Solution: Are you able to break chapatis with your fingers?

**Example of Forward/Backward Step**

Questionnaire: PROMIS Physical item bank
- Original: US English
- Are you able to push open a door after turning the knob?
- Target language: Dutch
- Concept: To explore patient’s ability to use his/her hand (functional ability)
- Problem: Doors with door knobs are quite uncommon in the Netherlands. Most doors have latches.
- Solution: Are you able to push open a door after pushing down the latch?

---

**An Approach: Translatability Assessment**

- Evaluation of the extent to which a PRO measure can be meaningfully translated into another language.

  A "meaningful translation" in the context of international clinical trials is one that is conceptually equivalent to the source text and culturally and linguistically appropriate in the target country to facilitate the comparison and pooling of data.

  The goal of a TA is to identify translation difficulties and suggest items to be modified or identified for deletion before embarking on the translation process itself.

**ISPOR Good Practices**


- Preparation
- Forward Translation
- Reconciliation
- Back Translation
- Back Translation Review
- Harmonization
- Cognitive Debriefing
- Review of all results and finalization
- Proofreading
- Final Report
How much can poor cross-cultural measurement affect statistical power?

- Study performed to explore the potential effect of the difference in the estimation of a PRO measure in a cultural group on the statistical power of the test comparing this measure between two treatment groups in the overall sample of a clinical trial.
- The impact of poor PRO measurement in a cultural subgroup can induce a notable drop in the study power and consequently reduce the chance of showing an actual treatment effect.
- This result illustrates the importance of the efforts to optimize cultural equivalence of PRO measures and standardization of assessments when pooling data in international clinical trials.

Example: Pain and/or Analgesic progression

<table>
<thead>
<tr>
<th>Country</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>258</td>
</tr>
<tr>
<td>France</td>
<td>141</td>
</tr>
<tr>
<td>Poland</td>
<td>71</td>
</tr>
<tr>
<td>Peru</td>
<td>23</td>
</tr>
<tr>
<td>UK</td>
<td>85</td>
</tr>
<tr>
<td>Argentina</td>
<td>98</td>
</tr>
<tr>
<td>Croatia</td>
<td>24</td>
</tr>
<tr>
<td>Netherlands</td>
<td>11</td>
</tr>
<tr>
<td>Italy</td>
<td>23</td>
</tr>
<tr>
<td>Germany</td>
<td>61</td>
</tr>
<tr>
<td>Russia</td>
<td>28</td>
</tr>
<tr>
<td>Israel</td>
<td>14</td>
</tr>
<tr>
<td>Belgium</td>
<td>46</td>
</tr>
<tr>
<td>Spain</td>
<td>42</td>
</tr>
<tr>
<td>Hungary</td>
<td>22</td>
</tr>
</tbody>
</table>

Summary

Cultural adaptation is a complex and challenging process

It is not a “word for word” translation
But a “world for world” translation
Global Stakeholder Engagement for Pediatric and Adult Drug Development

Andrew E. Mulberg, MD, FAAP
Division Deputy Director, Gastroenterology and Inborn Errors Products
FDA

International IBD (i-IBD) Working Group
- Convened in 2012 (monthly teleconference Jan - Dec 2012 and current)
  - Consisted of regulatory scientists from: U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, Pharmaceuticals and Medical Devices Agency of Japan (PMDA)
  - Goal: To facilitate global harmonization on regulatory issues affecting drug development in pediatric ulcerative colitis (UC). Topics discussed include: Extrapolation, Trial design, Disease outcome assessments, Efficacy endpoints, Pharmacokinetic considerations

International IBD (i-IBD) Working Group
- Recent Acceptance of Manuscripts for Publication: Journal of Pediatric Gastroenterology and Nutrition 2014
- Steps towards Harmonization for Clinical Development of Medicines in Pediatric Ulcerative Colitis — a Global Scientific Discussion
  - Part 1: Efficacy Endpoints and Disease Outcome Assessments
  - Steps towards Harmonization for Clinical Development of Medicines in Pediatric Ulcerative Colitis — Global Scientific Discussion
  - Part 2: Data Extrapolation, Trial Design, and Pharmacokinetics

GREAT 2012-2015
Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics
Session 3: Use of Clinical Outcome Assessment Tools in multinational trials: Qualification of Novel Methodologies

Maria Isaac, MSc., MD., PhD., MFPM., Psychiatrist
Senior Scientific Officer

Disclaimer
The views expressed in this presentation are the personal views of the speaker and may not be understood nor quoted as being made on behalf of or reflecting the position of EMA or one of its committees or working parties or any of the national agencies.

Other positions:
- Vice Chair of the Psychopharmacology Special Committee of the Council of the Royal College of Psychiatrists, UK.
- Previous: Consultant Psychiatrist & Co-Director of Psychopharmacology Evaluation Unit at the South London & Maudsley NHS trust in London and Honorary Senior Lecturer in the Department of Forensic and Neurodevelopmental Sciences at the Institute of Psychiatry, Kings College London, UK.

EU Guidance for Qualification of Novel Methodologies

- Voluntary, scientific pathway for innovative methods or drug development tools (e.g. biomarkers) not yet integrated in the drug development and clinical management paradigm
- One procedure with two outcomes:
  - Qualification Advice, OR
  - Qualification Opinion

Long-term benefits from EMA prespective: Speed-up the time to regulatory acceptance of novel approaches and time to new marketing authorisation applications.
Scientific Advice Working Party

standing WP of the CHMP (Reg. 726/2004)

multidisciplinary expert group (28) selected by expertise (not MS)

16 National Competent Authorities, 12 academia; members of EMA committees 3

CHMP, 1 CAT, 2 PDCO

CHMP peer-review, ad hoc discussions, adoption final advice letter

CMC: starting materials, spec, comparability, bridging...

non-clinical: overall toxicology plan registration, innovative models...

clinical pharmacology: PK/PD, modeling & simulation, BE...

clinical therapeutic areas: endpoints, population, comparator...

methodology, statistics: interim A, adaptive/seamless design...

network of external experts

Qualification of novel methodologies

CHMP qualification advice on future protocols and methods for further method development towards qualification, based on the evaluation of the scientific rationale and on preliminary data submitted, confidential

CHMP qualification opinion on the acceptability of a specific use of the proposed method (e.g. use of a BM) in a R&D context (non-clinical or clinical), based on the assessment of data, not product-specific. Qualification team, peer-review, public consultation, publication

The procedural route is not fixed but will follow the assessment of the data

Aims: SAWP/CHMP early involvement in the design of the strategy, with commitment to evaluate data from agreed studies and to provide opinion

Scope: Focus on acceptability of specific use of the proposed technology/BM developed for a specific intended use in the context of pharmaceutical R&D

(Context of Use)
FDA-EMA parallel Qualification ADVICE

- Encouraged by both Agencies
- Voluntary, at request of sponsor
- Discussion between FDA-EMA and tripartite meeting with sponsor
- Alignment of procedural flow between agencies is important and challenging: preparatory interactions with both agencies should start early
- Each Agency will issue separate responses to sponsor’s questions in line with their usual procedures
  - Increased dialogue between Agencies and sponsor from early stages of development
  - Exchange views, share expertise
  - Optimise and facilitate global development, meeting both agencies requirements

31 March 2015

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

Draft — Not for Implementation
Guidance for Industry
Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease

CHMP Opinion

The CHMP concludes that the EXACT PRO currently can be used as an exploratory endpoint in drug development trials for the prevention of exacerbations in COPD. Not only the EXACT total score, but also the derived metrics for severity, duration and frequency of exacerbation events appear to be sufficiently sensitive to changes in an individual patient’s disease condition.

The E-RS is a derivative instrument from the EXACT designed to address the need for a standardized PRO measure for evaluating the effect of treatment on the severity of respiratory symptoms in stable COPD.

The CHMP concludes that the E-RS can be used as an exploratory endpoint in drug development trials evaluating the effect of treatment on respiratory symptoms of COPD.
Links

EMEA guidance for companies requesting SA or PA

Qualification of novel methodologies for drug developments

Scientific guidelines

Thank you for your attention

Further information
[maria.isaac@ema.europa.eu]

European Medicines Agency
30 Churchill Place, Canary Wharf, London E14 5EE, United Kingdom
Telephone +44 (0) 20 3660 3300, Fax +44 (0) 20 3660 3323
Send a question via our website www.ema.europa.eu/contact

Follow us on @EMA_News